Crossject Société Anonyme
Crossject Société Anonyme, headquartered in France, is a pioneering company in the pharmaceutical industry, specialising in the development of innovative drug delivery systems. Founded in 2007, Crossject has made significant strides in creating its unique needle-free injection technology, which enhances patient comfort and compliance. The company focuses on several therapeutic areas, including pain management and emergency medicine, with its flagship product, Zeneo, designed to provide rapid and effective medication delivery. Crossject's commitment to innovation has positioned it as a leader in the market, with notable achievements in securing partnerships and advancing its product pipeline. With operations extending across Europe and beyond, Crossject continues to redefine the standards of drug administration, making healthcare more accessible and efficient.
DitchCarbon Score
How does Crossject Société Anonyme's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Crossject Société Anonyme's score of 26 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Crossject Société Anonyme's reported carbon emissions
Crossject Société Anonyme, headquartered in France, currently does not have available carbon emissions data for recent years, as indicated by the absence of specific figures. Furthermore, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the context of the pharmaceutical industry, it is increasingly important for companies to establish clear climate commitments and reduction targets to align with global sustainability goals. As the industry faces growing scrutiny regarding its environmental impact, Crossject's future initiatives may benefit from adopting industry-standard practices for emissions reporting and reduction.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Crossject Société Anonyme is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
